President Donald Trump’s recent executive order that temporarily bars travel from seven Muslim-majority countries to the United States will negatively affect research institutions, public health, and innovation, cancer organizations say.
In two back-to-back, all-day meetings, the FDA Oncologic Drugs Advisory Committee considered four thorny applications that the agency appeared to have been saving up as a result of the pause in activity that followed President Trump’s return to office.
